JD Supra

FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List

On April 15, 2026, the U.S. Food and Drug Administration ("FDA") announced a major shift in the regulatory landscape for compounded peptides. FDA updated its Bulk Drug Substances Nominated for Use in ...

FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...
NJBIZ

Frier Levitt to host webinar on GLP-1 legal risks

As demand for GLP-1 therapies rises, like weight-loss drug Wegovy and diabetes treatment Ozempic, so do the legal and regulatory complexities facing compounders, prescribers and other stakeholders. In ...
AOL

Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster GLP-1 drugs. But it won't end all compounding offerings. The company ...

FDA moves to exclude weight loss drugs from compounding chemicals list

The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- ...